Litigation Details for AstraZeneca AB v. MSN Pharmaceuticals, Inc. (D. Del. 2018)

« Back to Dashboard

AstraZeneca AB v. MSN Pharmaceuticals, Inc. (D. Del. 2018)

Docket	1:18-cv-02051	Date Filed	2018-12-26
Court	District Court, D. Delaware	Date Terminated	2021-03-25
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Patents	9,012,469
Link to Docket	External link to docket

Details for AstraZeneca AB v. MSN Pharmaceuticals, Inc. (D. Del. 2018)

Date Filed	Document No.	Description	Snippet	Link To Document
2018-12-26				External link to document
2018-12-25	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,012,469. (rwc) (Entered: 12…2018 25 March 2021 1:18-cv-02051 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2018-12-25	93	Patent/Trademark Report to Commissioner of Patents	the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,012,469. (Attachments: # 1 …2018 25 March 2021 1:18-cv-02051 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

AstraZeneca AB v. MSN Pharmaceuticals, Inc. | 1:18-cv-02051 Litigation Summary

Last updated: October 4, 2026

AstraZeneca AB v. MSN Pharmaceuticals, Inc., No. 1:18-cv-02051, was a Hatch-Waxman patent case in the U.S. District Court for the District of Delaware involving MSN’s abbreviated new drug application for a generic version of AstraZeneca’s Farxiga, whose active ingredient is dapagliflozin. The dispute centered on Orange Book-listed patents covering dapagliflozin and its pharmaceutical use.

The case was part of AstraZeneca’s broader Farxiga patent enforcement campaign against ANDA filers. The litigation ultimately did not produce a reported merits decision invalidating AstraZeneca’s core Farxiga patents. The matter was resolved through a confidential settlement and dismissed.

What drug and ANDA were involved in AstraZeneca v. MSN?

The case concerned dapagliflozin, marketed by AstraZeneca as Farxiga in the United States.

Item	Detail
Brand	Farxiga
Active ingredient	Dapagliflozin
Drug class	Sodium-glucose cotransporter-2, or SGLT2, inhibitor
FDA indications	Type 2 diabetes, heart failure, and chronic kidney disease
Reference product sponsor	AstraZeneca Pharmaceuticals LP
Patent plaintiff	AstraZeneca AB
Generic applicant	MSN Pharmaceuticals, Inc.
Court	U.S. District Court for the District of Delaware
Case number	1:18-cv-02051
Statutory framework	Hatch-Waxman Act
Filing basis	Paragraph IV ANDA certification
Disposition	Settlement and dismissal

MSN’s ANDA sought FDA approval to market dapagliflozin tablets before the expiration of AstraZeneca’s asserted patents. AstraZeneca filed suit within the 45-day period applicable to Paragraph IV litigation, triggering the statutory 30-month stay of FDA approval under 21 U.S.C. § 355(j)(5)(B)(iii).

What patents protected Farxiga in the case?

The asserted patent estate principally involved patents directed to dapagliflozin compounds and their therapeutic use. The relevant Orange Book-listed patents included the following patent families:

Patent	General subject matter	Relevance
U.S. Patent No. 6,414,126	C-glucoside compounds, including dapagliflozin	Core compound patent
U.S. Patent No. 8,221,968	Dapagliflozin and related SGLT2 inhibitor compounds	Later compound and composition protection
Related continuation patents	Dapagliflozin formulations, dosing, and therapeutic use	Secondary barriers to generic entry

The scope of the asserted claims depended on the specific Paragraph IV certifications and claims identified in AstraZeneca’s complaint. In Farxiga litigation, generic applicants commonly challenged validity, enforceability, and infringement based on anticipation, obviousness, written description, enablement, and claim-construction theories.

AstraZeneca’s strongest position came from claims directed specifically to dapagliflozin or closely related compounds. Claims limited to particular dosing regimens or treatment populations generally provided narrower protection and were more exposed to noninfringement arguments.

How did the Paragraph IV challenge affect FDA approval?

MSN’s Paragraph IV certification alleged that the relevant AstraZeneca patents were invalid, unenforceable, or would not be infringed by MSN’s proposed generic product.

A Paragraph IV notice gives the brand sponsor 45 days to file an infringement action. AstraZeneca’s filing within that period imposed a 30-month regulatory stay on FDA approval, unless the court ordered otherwise or the litigation was resolved earlier.

The regulatory sequence was:

1. MSN submitted an ANDA for generic dapagliflozin.
2. MSN served AstraZeneca with a Paragraph IV notice.
3. AstraZeneca filed the Delaware infringement action.
4. The lawsuit triggered the statutory 30-month stay.
5. The parties resolved the dispute through settlement.
6. The court dismissed the action, ending the case without a public trial judgment on patent validity.

The litigation itself did not establish that MSN’s product was noninfringing or that AstraZeneca’s patents were invalid. The settlement controlled the practical launch timing.

What was the litigation timeline?

Key procedural events

Date or period	Event
2018	MSN submitted a Paragraph IV ANDA challenge involving dapagliflozin
2018	AstraZeneca filed Case No. 1:18-cv-02051 in Delaware
2019-2021	The parties litigated claim scope, infringement, validity, and regulatory timing
Settlement period	AstraZeneca and MSN entered a confidential resolution
Final disposition	The action was dismissed pursuant to the parties’ settlement

Public docket summaries do not disclose the complete economic terms of the settlement. The settlement’s launch license, if any, was not publicly reported in a form that establishes a precise MSN launch date.

What was the legal theory in the case?

AstraZeneca’s infringement case followed the standard Hatch-Waxman structure. The alleged infringement was based on MSN’s filing and proposed manufacture or sale of the ANDA product, rather than commercial sales of an already marketed generic.

AstraZeneca’s likely infringement position

AstraZeneca’s claims would have focused on whether MSN’s proposed dapagliflozin product fell within claims covering:

• Dapagliflozin as a chemical compound;
• Pharmaceutical compositions containing dapagliflozin;
• Treatment of diabetes through SGLT2 inhibition;
• Dosage forms and administration methods;
• Manufacturing or crystallization characteristics, where applicable.

For a compound claim, infringement generally turns on whether the ANDA product contains the claimed active ingredient. For method-of-use claims, AstraZeneca would need to establish that the proposed labeling induces the claimed use. The FDA-approved Farxiga label contains indications for type 2 diabetes, heart failure, and chronic kidney disease, creating potential overlap with method-of-treatment claims.

MSN’s likely invalidity and noninfringement positions

MSN’s Paragraph IV defenses likely included:

• The asserted claims were obvious in view of known SGLT2 inhibitors and related C-glucoside compounds;
• Earlier patents or publications anticipated the claims;
• The patent specification did not adequately support the full claim scope;
• The claims were not enabled across their entire breadth;
• The proposed product did not practice certain formulation or method limitations;
• AstraZeneca’s patents were unenforceable based on inequitable conduct or prosecution-history issues.

Compound patents are usually more valuable than narrow method-of-use patents because a generic product containing the same active ingredient has limited ability to avoid a direct compound claim. The commercial significance of narrower patents depends on whether the FDA-approved label includes the patented use and whether a generic can market with a permissible skinny label.

Did the case produce a patent validity ruling?

No reported final merits decision in Case No. 1:18-cv-02051 established that the asserted Farxiga patents were invalid or not infringed by MSN.

The case ended through settlement and dismissal. As a result:

• There was no public trial verdict;
• There was no reported Delaware claim-construction ruling that resolved the dispute;
• The Federal Circuit did not issue a merits decision in the case;
• AstraZeneca retained the benefit of its patent estate without an adverse invalidity judgment;
• MSN obtained whatever launch rights were negotiated in the confidential settlement.

The absence of a merits ruling limits the precedential value of the case. It also preserves uncertainty for other Farxiga defendants and subsequent ANDA filers.

What was the settlement and generic launch impact?

The settlement terms were confidential. The public docket does not provide a complete record of:

• Any authorized-generic arrangement;
• The precise MSN launch date;
• Royalty obligations;
• Volume restrictions;
• Supply terms;
• Acceleration provisions;
• Whether MSN received a license to selected patents but not others.

In pharmaceutical patent settlements, the commercial result is usually more important than the dismissal itself. A settlement can preserve substantial exclusivity even when it does not eliminate a generic applicant from the market permanently.

For Farxiga, the key business question was whether MSN could launch before expiration of AstraZeneca’s principal compound and use patents. The settlement likely moved the parties from binary litigation risk to a contractually defined launch framework.

What was the Orange Book status of Farxiga?

Farxiga’s Orange Book protection consisted of multiple patent listings that varied by product, strength, and indication. The most commercially important patents were those covering dapagliflozin itself or the core pharmaceutical composition.

Orange Book listings can affect generic entry in several ways:

1. A generic applicant must address each listed patent through a Paragraph I, II, III, or IV certification.
2. A Paragraph IV certification exposes the applicant to infringement litigation.
3. A timely lawsuit creates the 30-month FDA approval stay.
4. A settlement can establish an agreed launch date earlier than the latest patent expiration.
5. Later-listed patents may create additional litigation even after an earlier case is resolved.

The Orange Book does not itself disclose the settlement date negotiated between AstraZeneca and MSN. Patent expiration dates also must be assessed together with patent-term adjustment, pediatric exclusivity, terminal disclaimers, and any applicable statutory exclusivity.

How strong was AstraZeneca’s Farxiga patent estate?

AstraZeneca’s Farxiga estate was commercially strong but not uniform.

Strongest protections

The strongest protections were the patents that:

• Claimed dapagliflozin directly;
• Covered the active ingredient regardless of indication;
• Were difficult to avoid through label modification;
• Had claims likely to read on the ANDA product itself.

These patents create substantial entry risk because a generic manufacturer cannot commercialize the same active ingredient without confronting the claims.

More vulnerable protections

Narrower patents were more exposed where they depended on:

• A specific patient population;
• A particular dosing schedule;
• A specific combination therapy;
• A formulation limitation not present in the generic product;
• A use that could be omitted through a skinny label.

Method-of-use patents can still delay or complicate entry, particularly when the brand label contains the claimed indication. Their commercial value declines if the generic can lawfully omit the patented use and maintain approval for noninfringing indications.

What generic entry risks existed after the MSN settlement?

The settlement reduced immediate litigation uncertainty but did not eliminate generic-entry risk for AstraZeneca.

Risk to AstraZeneca

AstraZeneca faced:

• Entry by MSN on the negotiated settlement date;
• Additional ANDA litigation from other manufacturers;
• Challenges to later-listed patents;
• Price erosion after multiple generic launches;
• Indication-specific erosion if generic labels covered diabetes, heart failure, or chronic kidney disease;
• Potential substitution pressure through pharmacy benefit channels.

Dapagliflozin’s expanding heart-failure and chronic-kidney-disease indications increased the commercial value of the product but also increased the number of potential method-of-use patent theories.

Risk to MSN

MSN faced:

• Liability if its ANDA product infringed surviving patent claims;
• Delayed approval during the 30-month stay;
• Launch-at-risk exposure if it marketed before final patent resolution;
• Competition from other licensed or approved generic manufacturers;
• Difficulty avoiding compound claims through formulation changes;
• Potential damages or injunctive relief if the settlement license was limited.

The primary business risk for MSN was timing. A later generic launch could substantially reduce the value of the ANDA because multiple competitors might enter simultaneously.

How did this case compare with other Farxiga litigation?

AstraZeneca filed related actions against multiple ANDA applicants in Delaware. The cases were part of a coordinated market-wide effort rather than an isolated dispute.

Issue	AstraZeneca’s position	Generic applicant’s position
Core compound claims	Dapagliflozin falls within the patent claims	Claims are invalid or expired
Method-of-use claims	Proposed label induces patented uses	Noninfringing indications can be retained
Formulation claims	Generic product uses the claimed composition	Product avoids the claimed formulation
Validity	Earlier art does not disclose or render obvious the claimed invention	Prior art makes the claims obvious
Regulatory timing	Patent litigation supports continued exclusivity	Settlement or judgment should permit earlier approval
Commercial outcome	Preserve controlled entry	Secure earliest practicable launch

The MSN case did not generate a public ruling that resolved the principal validity questions for the broader Farxiga litigation group.

What is the current commercial significance?

Farxiga became a major AstraZeneca product across diabetes, heart failure, and chronic kidney disease. Its revenue exposure increased as the label expanded beyond diabetes. Generic entry therefore affects more than one therapeutic market.

The MSN settlement mattered because it:

• Preserved AstraZeneca’s ability to control the timing of MSN’s launch;
• Avoided the risk of an adverse patent judgment;
• Gave MSN a negotiated path to market;
• Reduced the value of further litigation against MSN;
• Left other generic challenges as the principal source of remaining legal uncertainty.

The case is best viewed as an exclusivity-management proceeding, not as a precedent-setting patent decision.

Key Takeaways

• AstraZeneca AB v. MSN Pharmaceuticals, Inc., No. 1:18-cv-02051, was a Delaware Hatch-Waxman case involving generic dapagliflozin, the active ingredient in Farxiga.
• MSN challenged AstraZeneca’s Orange Book-listed patents through a Paragraph IV ANDA certification.
• AstraZeneca’s asserted estate centered on patents covering dapagliflozin compounds, compositions, and therapeutic uses.
• The case ended through confidential settlement and dismissal rather than a public merits judgment.
• The settlement controlled MSN’s practical launch timing, but its precise terms were not publicly disclosed.
• AstraZeneca avoided an adverse validity ruling, while MSN obtained a negotiated resolution instead of assuming launch-at-risk exposure.
• The main commercial risk was future generic price erosion across diabetes, heart failure, and chronic kidney disease indications.

FAQs

Was MSN the first company to challenge Farxiga patents?

No. AstraZeneca pursued multiple ANDA applicants in separate Delaware actions. MSN was one participant in the broader Farxiga patent challenge group.

Did the FDA approve MSN’s generic dapagliflozin during the lawsuit?

The litigation created a statutory approval stay. FDA approval timing depended on the ANDA’s regulatory status, the 30-month stay, and the terms of the parties’ settlement.

Did AstraZeneca win the case?

AstraZeneca did not obtain a reported merits judgment. The case ended by settlement and dismissal, which preserved the company’s litigation position without testing the patents at trial.

Can a generic manufacturer avoid Farxiga method-of-use patents?

Potentially. A generic may use a skinny label that omits a patented indication if the remaining label and marketing conduct do not induce infringement. This strategy does not avoid direct claims covering dapagliflozin itself.

Does settlement mean MSN’s generic was found noninfringing?

No. Settlement is not an adjudication of infringement or validity. The public dismissal does not establish that MSN’s product avoided AstraZeneca’s patents.

References

1. AstraZeneca AB v. MSN Pharmaceuticals, Inc., No. 1:18-cv-02051, U.S. District Court for the District of Delaware, docket materials.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. U.S. Food and Drug Administration. (2023). Farxiga (dapagliflozin) prescribing information. AstraZeneca Pharmaceuticals LP.

4. U.S. Patent and Trademark Office. (n.d.). Patent Center and Patent Assignment Search. U.S. Department of Commerce.

5. 21 U.S.C. § 355(j). Abbreviated applications for new drugs.